IMPACT OF PCV10 INTRODUCTION ON NASOPHARYNGEAL CARRIAGE OF STREPTOCOCCUS PNEUMONIAE IN HEALTHY CHILDREN IN RURAL AND URBAN NEPAL (ID 531)

Session Name
Vaccines - Impact of Vaccine programs and Serotype Replacement
Presenter
  • Madhav Chandra Gautam, Nepal
Authors
  • Madhav Chandra Gautam, Nepal
  • Sonu Shrestha, United Kingdom
  • Sanjeev M. Bijukchhe, Nepal
  • Meeru Gurung, Nepal
  • Bhishma Pokhrel, Nepal
  • Merryn Voysey, United Kingdom
  • Peter J. O'Reilly, United Kingdom
  • Sarah Kelly, United Kingdom
  • Ganesh Shah, Nepal
  • Laxmi Lama, Nepal
  • Pratistha Maskey, Nepal
  • Stephen Thorson, Nepal
  • David Murdoch, New Zealand
  • Maria Deloria Knoll, United States of America
  • Dominic Kelly, United Kingdom
  • Shrijana Shrestha, Nepal
  • Andrew J. Pollard, United Kingdom

Abstract

Background

The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced in Nepal in 2015. We compared the nasopharyngeal carriage of PCV10 and non-PCV10 serotypes of pneumococcus between pre-vaccine (2015) and post-vaccine (2017-2018) years in two different regions of Nepal.

Methods

Nasopharyngeal samples obtained in healthy Nepalese children aged 6-59 months in urban (Patan, Kathmandu) and 6-23 months in rural (Okhaldhunga) settings were transported in STGG (Skim Milk-Tryptone-Glucose-Glycerol) media, cultured for pneumococcus and serotyped by the Quellung method.

Results

The carriage prevalence decreased for all PCV10-type serotypes except 7F in both the settings. PCV10-type prevalence decreased from 29.7% in rural and 17.2% in urban children pre-vaccine to 9.0% and 8.6% post-vaccine, respectively. Pre-vaccine, the most frequently found serotypes in both settings were 19F, 6B, 14. Post-vaccine, the non-PCV10 serotypes were more common; serotypes 34, 6C, 19A and 15B were most common in rural and 6A, 34, 11A, 6C and 15B in urban settings.

Conclusions

Since the introduction of PCV10, carriage prevalence of PCV10 serotypes have reduced and non-PCV10 serotypes have increased in both settings raising the possibility of replacement disease. Continued monitoring of changes in PCV10-serotypes and non-PCV10 serotypes, especially those covered by PCV13, is important to assess vaccine impact.

Hide